PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26026F0013PHARM - XYWAV — Jazz Pharmaceuticals, Inc

Jazz Pharmaceuticals, Inc holds $4.5M across 57 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 2 related awards under parent 36F79719D0205. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

260-Network Contract Office 20 (36C260)

Awarding office

Jazz Pharmaceuticals, Inc

Recipient

Sep 30, 2026

PoP end

$231K

Obligated

$240K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Jazz Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26026F0013

Also listed as36C260-26-F-0013

Also listed as36F79719D0205-36C26026F0013

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentJazz Pharmaceuticals, Inc

CAGE4RTH5

UEIH9AXCNRA5NE6

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0205

Place of performanceSAINT LOUIS MO

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2025

PoP end (current)Sep 30, 2026

Obligated$231K

Current value$240K

Potential value$240K

PHARM - XYWAV is a federal award for 260-Network Contract Office 20 (36C260) held by Jazz Pharmaceuticals, Inc. Estimated value $240K ($231K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: SAINT LOUIS MO.

Recompete timing

Public

● Expiring in 40 days

Current PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Jazz Pharmaceuticals, Inc — $4.5M obligated across 57 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$4.5M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C26026F0027

XYWAV 500MG/ML ORAL SOLUTION, AND XYREM 500MG/ML ORAL SOLUTION

$456K

Sep 30, 2026

36C26026F0012

PHARM - XYREM

$210K

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26026F0013?

36C26026F0013 (PHARM - XYWAV) is a 260-Network Contract Office 20 (36C260) award with a potential value of $240K, currently held by Jazz Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-26-F-0013?

36C260-26-F-0013 is the dashed form of PIID 36C26026F0013 (PHARM - XYWAV), held by Jazz Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26026F0013?

260-Network Contract Office 20 (36C260) awarded 36C26026F0013 to Jazz Pharmaceuticals, Inc (potential $240K).

Who is the incumbent on 36C26026F0013?

Jazz Pharmaceuticals, Inc is the incumbent with $4.5M across 57 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does Jazz Pharmaceuticals, Inc’s 36C26026F0013 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action May 8, 2026